PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the “Company” or “GenSight”), a biopharma company focused on developing and commercializing innovative gene therapies for…
Author: Business Wire
GenSight Biologics annonce la conversion partielle des obligations convertibles et l'exercice de l'intégralité des bons de souscription d'actions par Kreos Capital
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME) (Paris:SIGHT) (la « Société » ou « GenSight »), société biopharmaceutique dédiée au développement et à la commercialisation de thérapi…
Neuromyelitis Optica (Devic's Syndrome) Pipeline Review, H2 2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Neuromyelitis Optica (Devic’s Syndrome) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering. Neuromyelitis Optica – Pipeline Review, H2 2020, provides comprehensive information on…
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,…
中外製藥的Enspryng成為臺灣核准的首款用於泛視神經脊髓炎(NMOSD)的藥物
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO:4519)宣布，中外製藥的獨資子公司Chugai Pharma Taiwan Ltd.的Enspryng®獲得臺灣食品藥物管理署(TFDA)的進口藥物許可，Enspryng®用於治療抗水通道蛋白-4(AQP4)抗體陽性的泛視神經脊髓炎(NMOSD) 12歲以上成人和青少年患者。 中外製藥總裁兼營運長Osamu Okuda博士表示：「我們很高興的…
GenSight Biologics annonce la publication dans Science Translational Medicine des résultats de l’essai pivot de phase III REVERSE et d’une étude sur des primates avec LUMEVOQ®
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le tr…
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative dis…
My Eyelab Opens New Store in Atlanta Area
CONYERS, Ga.–(BUSINESS WIRE)–My Eyelab, a leading optical retailer offering accessible and affordable eye care and eyewear, opened its newest location in Conyers, GA on Monday, December 7. Located at 1285 GA-138, the new store marks My Eyelab’s 90th …
My Eyelab Signs Agreement to Open Eight New Stores in Texas with Multi-Unit Franchise Group
AUSTIN, Texas–(BUSINESS WIRE)–My Eyelab, a retail brand of Now Optics, announced today it has signed an agreement which will bring eight new franchise stores to the Austin and Fort Worth markets. Growth in the coming months will be driven by a trio o…
Introducing EyeQue VisionCheck 2 – the World’s Most Powerful Do-It-Yourself Smartphone Vision Test
NEWARK, Calif.–(BUSINESS WIRE)– #digitalhealth–EyeQue introduces the VisionCheck 2, its most powerful smartphone-powered vision test yet. Now available for pre-order on Kickstarter.
Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Pipeline Review, H2 2020 – Therapeutic Assessment of 14 Companies, Drug Profiles, Dormant Projects, Product Development Milestones – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering. Leber’s Hereditary Optic Neuropathy – Pipeline Review, H2 2020, prov…
Global Choroidal Neovascularization Market (2020 to 2025) – Industry Trends, Share, Size, Growth, Opportunity and Forecast – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025” report has been added to ResearchAndMarkets.com’s offering. The global choroidal neovascularization mark…
Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)– #NMOSD–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced Chugai Pharma Taiwan Ltd., a wholly-owned subsidiary of Chugai, obtained an import drug license from the Taiwan Food and Drug Administration (TFDA) for Chugai’s Ens…
Mojo Vision and Menicon Announce Joint Development Agreement on Smart Contact Lens Products
SARATOGA, Calif.–(BUSINESS WIRE)–Mojo Vision, the Invisible Computing company, and Menicon, Japan’s first and largest contact lens manufacturer, today announced that both companies have entered into a joint development agreement. Mojo Vision is devel…
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseas…
TILAK HEALTHCARE SIGNE UN NOUVEAU PARTENARIAT EN OPHTALMOLOGIE AVEC NOVARTIS POUR SE DÉVELOPPER À L'INTERNATIONAL
PARIS–(BUSINESS WIRE)–Tilak Healthcare, société pionnière spécialisée dans le développement de jeux mobiles avec modules médicaux destinés au suivi de patients atteints de maladies chroniques, a le plaisir d’annoncer un nouvel accord de co-promotion …
Tilak Healthcare Inks New Partnership Agreement in Ophthalmology With Novartis to Expand Internationally
PARIS–(BUSINESS WIRE)–Tilak Healthcare, a digital therapeutics pioneer specializing in the development of mobile medical application games used as monitoring and rehabilitation tools for chronic diseases, is proud to announce a framework agreement wi…
Global $642 Million Fundus Camera (Mydriatic, Non-Mydriatic, Hybrid, ROP) Market to 2026 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Fundus Camera Market Share by Product Type (Mydriatic, Non-Mydriatic, Hybrid, ROP), End-Users (Ophthalmic & Optometrist Offices, Ophthalmology Clinics, Hospitals), Regions, and Companies” report has been added to Resea…
Kubota Vision Announces Submission of Novel VAP-1 Inhibitors to the NCI Developmental Therapeutics Program for Screening in Cancer Cell Lines
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the submission of novel Vascular Adhe…
Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases
SOUTH SAN FRANCISCO, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases